Novel Chemically Modified Analogues of Neuropeptide Y for Tumor Targeting
Denise Zwanziger(Leipzig University), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), Lutz Lehmann(Bayer (Germany)), Stephanie Sieger(Bayer (Germany)), Irfan Ullah Khan(Institute of Radiotherapy and Nuclear Medicine), Ines Neundorf(University of Cologne), Ludger M. Dinkelborg(Bayer (Germany)), Matthias Friebe(Bayer (Germany))
Cited by 60
Related Papers
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin
|Endocrinology|2006|432
Herbal drugs and phytopharmaceuticals
|Pharmaceutica Acta Helvetiae|1995|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
|European Journal of Pharmacology|1994|374